Response to imatinib plus sirolimus in advanced chordoma

Annals of Oncology

Volumn 20, Issue 11, 2009, Pages 1886-1894

  Stacchiotti, Silvia ^a   Marrari, A ^a   Tamborini, E ^a   Palassini, E ^a   Virdis, E ^a   Messina, A ^a   Crippa, F ^a   Morosi, C ^a   Gronchi, A ^a   Pilotti, S ^a   Casali, P G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chordoma; Imatinib; MTOR; Rapamycin; Sarcoma; Sirolimus

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; NILOTINIB; PROTEIN KINASE B; RAPAMYCIN;

ABSCESS; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER RADIOTHERAPY; CANCER RESISTANCE; CHORDOMA; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVATION; FEMALE; HERPES LABIALIS; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INFECTION; LEG EDEMA; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; ORTHOPEDIC SURGERY; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTOPENIA; TUMOR VOLUME; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CHORDOMA; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ONCOGENE PROTEIN V-AKT; PIPERAZINES; PYRIMIDINES; SACRUM; SIROLIMUS; SKULL BASE NEOPLASMS; SPINAL NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 71049122718     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp210     Document Type: Article

References (31)

1. Newton H. Chordoma. In Raghavan D, Brecher ML, Johnson DH, et al. (eds) Textbooks of Uncommon Cancer, 3rd edition. Chichester, UK: John Wiley & Sons Ltd 2006; 614-625.
2. Mirra JM, Della Rocca C, Nelson SD, Mertens F. Chordoma. In Fletcher CDM, Unni KK, Mertens F (eds): Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press 2002; 316-317.
3. Higinbotham NL, Philips RF, Farr HW, Hustu HO. Chordoma. Thirty-five-year study at Memorial Hospital. Cancer 1967; 20: 1841-1850.
4. Chambers PW, Schwinn CP. Chordoma: A clinico-pathologic study of metastasis. Am J Clin Pathol 1979; 72: 765-776.
5. York JE, Kaczaraj A, Abi-Said D et al. Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery 1999; 44: 74-79.
6. Baratti D, Gronchi A, Pennacchioli E et al. Chordoma: Natural history and results in 28 patients treated at a single institution. Ann Surg Oncol 2003; 10: 291-296.
7. Tzortzidis F, Elahi F, Wright D et al. Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordomas. Neurosurgery 2006; 59: 230-237; discussion 230-237.
8. Boriani S, Bandiera S, Biagini R et al. Chordoma of the mobile spine: fifty years of experience. Spine 2006; 31: 493-503.
9. Fleming GF, Heimann PS, Stephens JK et al. Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases. Cancer 1993; 72: 714-718.
10. Chugh R, Dunn R, Zalupski MM et al. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol 2005; 23: 3597-3604.
11. Tamborini E, Miselli F, Negri T et al. Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin Cancer Res 2006; 12: 6920-6928.
12. Casali PG, Messina A, Stacchiotti S et al. Imatinib mesylate in chordoma. Cancer 2004; 101: 2086-2097.
13. Hof H, Welzel T, Debus J. Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie 2006; 29: 572-574.
14. Stacchiotti S, Grosso F, Dileo P et al. Antitumor activity of imatinib plus cisplatin in two patients with advanced chordoma. Proceedings of the 12th Annual Connective Tissue Oncology Society Meeting 2006: 58 (Abstr 725).
15. Schmelzle T, Hall MN. mTOR, a central controller of cell growth. Cell 2000; 103: 253-262.
16. Atkins MB, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-918.
17. Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist 2007; 12: 1007-1018.
18. Kahan BD, Camardo JS. Rapamycin: Clinical results and future opportunities. Transplantation 2001; 72: 1181-1193.
19. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-206.
20. Choi H, Charnsangavej C, Faria SC et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: 1753-1759.
21. Stacchiotti S, Collini P, Messina A et al. Tumor response assessment in high grade soft tissue sarcomas (STS): A pilot study to assess the correlation between radiological and pathological response using both RECIST and Choi's criteria. Radiology 2009. doi: 10.1148/ radiol.2512081403.
22. Young H, Baum R, Cremerius U et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations - European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-1782.
23. Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas: EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38: 543-549.
24. Iwenofu OH, Lackman RD, Staddon AP et al. Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol 2008; 21: 231-237.
25. Stommel JM, Kimmelman AC, Ying H et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007; 318: 287-290.
26. Kinkade CW, Castillo-Martin M, Puzio-Kuter A et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008; 118: 3051-3064.
27. Carracedo A, Ma L, Teruya-Feldstein J et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118: 3065-3074.
28. Grant S. Cotargeting survival signaling pathways in cancer. J Clin Invest 2008; 118: 3051-3064.
29. MacDonald A, Scarola J, Burke JT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000; 22 (Suppl B): B101-B121.
30. Cattaneo D, Merlini S, Pellegrino M et al. Therapeutic drug monitoring of sirolimus: Effect of concomitant immunosuppressive therapy and optimization of drug dosing. Am J Transplant 2004; 4: 1345-1351.
31. O'Reilly KE, Rojo F, She QB et al. mTOR inhibition induces upstream receptor tyrosine kinase signalling and activates Akt. Cancer Res 2006; 66: 1500-1508.